Understanding Cost and Value in Hepatitis C Therapy

Area of Science:

• Hepatology
• Infectious Diseases
• Health Economics

Background:

• Hepatitis C virus (HCV) infection treatment access is hindered by high therapy costs.
• Newer HCV regimens are cost-effective but face reimbursement challenges, particularly for early-stage disease, due to payer budget constraints in the US.

Purpose of the Study:

• To summarize strategies for maximizing patient access to appropriate hepatitis C virus (HCV) therapies.
• To address the economic barriers in accessing novel HCV treatments.

Main Methods:

• Summarizes a presentation on managing HCV in the era of new small molecule therapies.
• Focuses on practical approaches to overcome treatment access limitations.
• Highlights the importance of administrative support and patient engagement.

Main Results:

• Dedicated staff for prior authorizations and appeals are crucial for securing treatment approval.
• Documenting and sharing successful prior authorization strategies can improve collective success rates.
• Effective patient communication is vital to prevent patients from being lost to care.

Conclusions:

• Implementing dedicated administrative support and robust patient communication strategies can enhance access to cost-effective HCV treatments.
• Overcoming payer-related reimbursement hurdles is key to ensuring timely and appropriate HCV care.
• Proactive management of access barriers is essential for successful HCV treatment outcomes.